Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?
Velia Chiara Di Maio(University of Rome Tor Vergata), L. Lambiase, Valeria Cento(Rostov State Medical University), Giovanni Battista Gaeta, Antonio Grieco(Università Cattolica del Sacro Cuore), C. D’Ambrosio, Gabriella d’Ettorre(Policlinico Umberto I), Roberto Gulminetti(University of Pavia), Matteo Bolis(Ospedale Amedeo di Savoia), Bianca Bruzzone(Ospedale Policlinico San Martino), Vincenza Calvaruso(University of Palermo), Stefania Paolucci(Policlinico San Matteo Fondazione), Andrea De Luca(Agostino Gemelli University Polyclinic), M. Aragri(University of Rome Tor Vergata), V. Boccaccio(Humanitas University), Nicola Caporaso(Federico II University Hospital), Sergio Babudieri(University of Sassari), Fausto Baldanti(University of Pavia), S. Francioso, Ada Bertoli(IRCCS Policlinico San Donato), Valeria Ghisetti(Ospedale Amedeo di Savoia), G. Gubertini, Giorgio Barbarini(Humanitas University), Vanni Borghi(University of Modena and Reggio Emilia), M. Angélico, Teresa Pollicino(University of Messina), Massimo Andreoni(University of Rome Tor Vergata), Giovanni Raimondo(University of Messina), P. Colombatto(Azienda Ospedaliera Universitaria Pisana), Nicola Coppola(University of Campania "Luigi Vanvitelli"), Alessia Ciancio(Department of Medical Sciences), Francesca Ceccherini‐Silberstein(University of Cologne), Alessia Giorgini(Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo), Antonio Ciaccio(University of Turin), William Gennari(University of Modena and Reggio Emilia), Pietro Andreoné, Maurizia Rossana Brunetto(University of Pisa), Lucio Boglione(Ospedale Amedeo di Savoia), Raffaele Cozzolongo, Silvia Galli(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Savino Bruno(Humanitas University), Silvia Barbaliscia(University of Rome Tor Vergata), Carlo Federico Perno(Centre International De Reference Chantal Biya), Antonio Craxı̀(University of Palermo), Stefano Bonora(Ospedale Amedeo di Savoia), Giuseppina Brancaccio, Giovanni Di Perri(University of Turin), Maurizio Zazzi(University of Siena), Pierluigi Cacciatore(Azienda USL di Pescara), Antonio Di Biagio
Cited by 31
Related Papers
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease†
|Hepatology|2009|1.4k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|998